Detalhe da pesquisa
1.
Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.
Future Oncol
; 16(1s): 9-13, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31916463
2.
Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group.
Crit Rev Oncol Hematol
; 193: 104217, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38040072
3.
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
Ther Adv Med Oncol
; 11: 1758835919895755, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31903098
4.
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma.
Oncol Res Treat
; 40(6): 364-369, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28472807
5.
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Cancer Chemother Pharmacol
; 73(2): 299-307, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24258456
6.
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: a new category of patients for clinical studies?
J Am Geriatr Soc
; 53(6): 1078-80, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15935045
7.
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Cancer
; 112(7): 1555-61, 2008 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18286536